Therefore, we designed a phase Ib trial with a chemotherapy-free regimen of nivolumab and ipilimumab combined with intralesional T-VEC for neoadjuvant treatment of localized, operable HER2-negative breast cancer. Here, ERBB2 is linked to breast cancer.